2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163672
    Glucocorticoid receptor modulator 3 2688785-13-7 98%
    Glucocorticoid receptor modulator 3 (Payload 6) is a thioester-containing glucocorticoid receptor modulator (IC50=0.6 nM). Glucocorticoid receptor modulator 3 is designed to inactivate unconjugated payloads rapidly through liver metabolism, thereby minimizing systemic exposure. Glucocorticoid receptor modulator 3 can be utilized in the development of antibody-drug conjugates (ADCs) targeting autoimmune diseases.
    Glucocorticoid receptor modulator 3
  • HY-163752
    CS17919 2379346-41-3 98%
    CS17919 is a potent, selective and orally active ASK1 inhibitor with an IC50 of 22.52 nM. CS17919 shows anti-inflammatory and antifibrotic effects. CS17919 can be used for the study of metabolic-related kidney and liver diseases.
    CS17919
  • HY-163832
    FPPS-IN-2 98%
    FPPS-IN-2 (compound 4a) is a potent and orally active HFPPS inhibitor with an IC50 value of 1.108 µM. FPPS-IN-2 has the potential for the research of osteoporosis.
    FPPS-IN-2
  • HY-163839
    DS-1093a 1296273-51-2 98%
    DS-1093a is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, with an EC50 of 0.49 μM in Hep3B cell EPO production. DS-1093a can be used in the research of renal anemia.
    DS-1093a
  • HY-163899
    (+)-Crinatusin A1 98%
    (+)-Crinatusin A1 (Compound (+)- 4) is a chalcone-monoterpene hybrid, which can be isolated from Cleistocalyx operculatus. (+)-Crinatusin A1 is an inhibitor for protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.9 μM. (+)-Crinatusin A1 exhibits potential as an antidiabetic agent.
    (+)-Crinatusin A1
  • HY-163907
    α-Glucosidase-IN-71 98%
    α-Glucosidase-IN-71 (Compound 7h) is a competitive α-glucosidase inhibitor (IC50: 98.0 µM). α-Glucosidase-IN-71 can be used for research of carbohydrate-related diseases, especially type 2 diabetes mellitus.
    α-Glucosidase-IN-71
  • HY-164092
    Eicosanoyl-CoA 15895-27-9 98%
    Eicosanoyl-CoA is a reduction metabolite of (E)-2,3 eicosanoyl-CoA.
    Eicosanoyl-CoA
  • HY-164257
    2-trans-4-trans-Decadienoyl-CoA 83945-34-0 98%
    2-trans-4-trans-Decadienoyl-CoA is a coenzyme A derivative.
    2-trans-4-trans-Decadienoyl-CoA
  • HY-164357
    14-Deoxypoststerone 1360460-98-5 98%
    14-Deoxypoststerone is a steroid compound, a derivative of a steroid hormone.
    14-Deoxypoststerone
  • HY-16448R
    Saxagliptin hydrochloride (Standard) 709031-78-7
    Saxagliptin (hydrochloride) (Standard) is the analytical standard of Saxagliptin (hydrochloride). This product is intended for research and analytical applications. Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research.
    Saxagliptin hydrochloride (Standard)
  • HY-164532
    NS3736 265646-94-4 98%
    NS3736 is an orally effective chloride channel inhibitor that can be used for the research of osteoporosis. NS3736 targets the CIC-7 channel in osteocytes, blocks osteoclast acidification and resorption in vitro, with IC50=30 μM. In a rat model of ovariectomy-induced osteoporosis, NS3736 can enhance bone strength and bone density.
    NS3736
  • HY-164634
    CLIK-148 215098-90-1 98%
    CLIK-148 is a highly selective, irreversible and orally active cysteine protease inhibitor, primarily targeting Cathepsin L. CLIK-148 effectively inhibits the Cathepsin L-dependent degradation of HMG-CoA reductase in the endoplasmic reticulum (ER) membrane. CLIK-148 inhibits the processing of proCCK by Cathepsin L, thereby reducing the production of CCK8 (HY-P0093). CLIK-148 inhibits the degradation of type I collagen by osteoclasts' secreted Cathepsin L, reducing tumor-induced bone metastasis and malignant hypercalcemia. CLIK-148 can be used for the studies of bone metabolism disorders and regulation of neuropeptide processing.
    CLIK-148
  • HY-164698
    CP-470711 300548-99-6 98%
    CP-470711 is an orally active and potent and selective sorbitol dehydrogenase (SDH) inhibitor with an IC50=10 nM for human SDH and IC50=17 nM for rat SDH. CP-470711 is promising for research of chronic complications related to type 2 diabetes mellitus, such as neuropathy and nephropathy.
    CP-470711
  • HY-164809
    Desisopropyle-belumosudil 911417-89-5 98%
    KD025m1 is a novel selective ROCK2 inhibitor. KD025m1 has good anti obesity, improved insulin sensitivity, and blood glucose control effects. KD025m1 can be used to study metabolic diseases such as diabetes and obesity.
    Desisopropyle-belumosudil
  • HY-164813
    oxLig-1 352523-18-3 98%
    oxLig-1 (7-Ketocholesteryl-9-carboxynonanoate) is the lipid moiety of oxidized low-density lipoprotein (oxLDL) and is a key ligand for β-glycoprotein I (β(2)-GPI). oxLig-1 causes nuclear translocation by activating the NF-κB pathway. oxLig-1 can be used in the study of atherosclerosis (AS).
    oxLig-1
  • HY-164870
    FFAR1/FFAR4 agonist-1 2839486-16-5 98%
    FFAR1/FFAR4 agonist-1 (compound 83) is a FFAR1/FFAR4 agonist with the EC50 of 1 nM A and 4nM for FFAR1 and FFAR4, respectively. FFAR1/FFAR4 agonist-1 can be used for study of glycemic control.
    FFAR1/FFAR4 agonist-1
  • HY-164909
    PZ-3022 2170608-85-0 98%
    PZ-3022 is an orally active allosteric agonist of pantothenate kinase (PanK) with an EC50 of 5.3 nM against PanK3. PZ-3022 antagonizes the inhibitory effect of C3-CoA. PZ-3022 increases CoA levels in cells and the liver, upregulates CoASH and C2-CoA, downregulates C3-CoA, and restores impaired TCA cycle and mitochondrial function. PZ-3022 can be used for the research of propionic acidemia and metabolic CoA deficiency.
    PZ-3022
  • HY-164910
    AHL-Pu-2 1838570-66-3 98%
    AHL-Pu-2 is the clickable electrophilic purine. AHL-Pu-2 can be used to directly quantify protein-RNA interactions on proteins through photoaffinity competition with 4-thiouridine (4SU)-labeled RNA in cells.
    AHL-Pu-2
  • HY-164913
    PSB-SB-1203 1399049-80-9 98%
    PSB-SB-1203 (Compound 25b) is a dual CB1/CB2 ligand that blocks CB1 but activates CB2 receptors (CB1 Ki 0.244 μM; CB2 Ki 0.210 μM, EC50 0.054 μM). PSB-SB-1203 is promising for research of obesity and cancers.
    PSB-SB-1203
  • HY-164915
    5-InoAz 1218932-97-8 98%
    5-InoAz is an inositol analogue used as a metabolic probe for labeling the mycobacterial cell envelope. 5-InoAz integrates into cell envelope glycolipids [phosphatidylinositol mannoside (PIM), PIM-anchored lipomannan (LM), and lipoarabinomannan (LAM)].
    5-InoAz
Cat. No. Product Name / Synonyms Application Reactivity